Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) has shared an update.
Neurizon Therapeutics has notified holders of its NUZOA listed options that these securities, each exercisable at $0.15 for one fully paid ordinary share, will expire at 5:00pm AEST on 30 April 2026. Official quotation of NUZOA on the ASX will cease on 24 April 2026, and option holders may choose to exercise, sell before trading stops, or allow the options to lapse, a timetable that may influence near-term trading dynamics and shareholder decisions given the current share price sits below the exercise price.
The company outlined that there is no obligation to exercise the options and highlighted recent market prices for its ordinary shares, which have traded between $0.076 and $0.105 over the prior three months. This expiry process clarifies the capital structure timeline for Neurizon and provides investors with a defined window to convert options into equity or exit positions before the securities are removed from quotation.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative diseases, led by its investigational drug candidate NUZ-001 for amyotrophic lateral sclerosis, the most common form of motor neurone disease. The company aims to accelerate access to ALS therapies while exploring broader neurodegenerative applications through international collaborations and clinical programs.
Average Trading Volume: 637,417
Technical Sentiment Signal: Sell
Current Market Cap: A$57.29M
See more data about NUZ stock on TipRanks’ Stock Analysis page.